Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTB-3119M
- Development stage
- Unknown
- Lead developer
- Institute of Materia Medica, Chinese Academy of Medical Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NTB-3119M is a novel granule formulation of rifapentine, a long-acting rifamycin derivative, developed by Qingdao Baiyang Pharmaceutical for the treatment and prevention of tuberculosis. As a rifamycin, it functions by inhibiting the beta subunit of DNA-dependent RNA polymerase in *Mycobacterium tuberculosis*, thereby preventing RNA synthesis and subsequent protein production. This granule formulation is specifically designed to enhance patient adherence and provide a more flexible dosing option, particularly for pediatric patients or those with difficulty swallowing tablets. NTB-3119M is currently in Phase 3 clinical development for the treatment of latent tuberculosis infection.
- Other names
- Rifapentine granules
02
Targets
rpoB (DNA-directed RNA polymerase subunit beta)
Beyond the preview
Go deeper on NTB-3119M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTB-3119M.